Armenian Medical NetworkHealth.am
Health centers
CancerHeart & Blood VesselsBrain & NervesMental HealthDiabetes & HormonesWeight & NutritionWomen's HealthPregnancy & FertilityChildren's HealthSexual HealthMen's HealthInfections, HIV & STIsLungs, Asthma & AllergiesDigestive HealthBones, Joints & PainSkin, Hair & BeautyEyes, Ears & TeethAddictionSleepHealthy AgingPublic HealthMedicines & Treatments

References



  1. Newman B, Austin MA, Lee M et al. Inheritance of human breast cancer: Evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci USA 1988; 85:3044-3048.

  2. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-1689.

  3. Narod SA, Feunteun J, Lynch HT et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991; 338:82-83.

  4. Steichen-Gersdorf E, Gallion HH, Ford D et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 1994; 55:870-875.

  5. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.

  6. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265:2088-2090.

  7. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789-792.

  8. Zhang H, Tombline G, Weber BL. BRCA1, BRCA2, and DNA damage response: Collision or collusion? Cell 1998; 92:433-436.

  9. Malone KE, Daling JR, Thompson JD et al. BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 1998; 279:922-929.

  10. Newman B, Mu H, Butler LM, Millikan RC et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998; 279:915-921.

  11. Berchuck A, Heron KA, Carney ME et al. Frequency of germline and somatic

  12. BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998; 4:2433-2437.

  13. Rubin SC, Blackwood MA, Bandera C et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998; 178:670-677.

  14. Stratton JF, Gayther SA, Russell P et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336:1125-1130.

  15. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60:1013-1020.

  16. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer Families. Am J Hum Genet.1998; 62:676-689.

  17. Tonin P, Weber B, Offit K et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996; 2:1179-1183.

  18. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401-1408.

  19. Kleihues P, Schauble B, Zur HA et al. Tumors associated with p53 germline mutations: A synopsis of 91 families. Am J Pathol 1997; 150:1-13.

  20. Schrager CA, Schneider D, Gruener AC et al. Clinical and pathological features of breast disease in Cowden's syndrome: An underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 1998; 29:47-53.

  21. Anonymous. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997; 349:1505-1510.

  22. Watson P, Marcus JN, Lynch HT. Prognosis of BRCA1 hereditary breast cancer. Lancet 1998; 351:304-305.

  23. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277:997-1003.

  24. Eisinger F, Alby N, Bremond A et al. Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee. Ann Oncol 1998; 9:939-950.

  25. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340:77-84.

  26. Grann VR, Panageas KS, Whang W et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1- positive or BRCA2-positive patients. J Clin Oncol 1998; 16:979-985.

  27. Schrag D, Kuntz KM, Garber JE et al. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336:1465-1471.

  28. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388.

  29. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 1998; 339:424-428.

  30. Robson M, Levin D, Federici M et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999; 91:2112-2117.